He is a partner at Odlander Fredrikson/HealthCap, the life sciences venture capital firm, which was also the principal shareholder of Nordic Nanovector at 31 December 2016. He has also gained more than 15 years of investment banking experience, mainly with Aros Securities in Sweden. In his final position with Aros Securities, as a director of the corporate finance department, he specialised in the areas of merger transactions, initial public offerings and equity incentive programmes. Prior to this, Mr Samuelsson was head of research at Aros Securities. He currently holds board positions in several companies, including Targovax ASA, Nordic Vision Clinics AS, Oncopeptides AB, RSPR Pharma AB, RSPR Inventive AS, Ancilla AB, Cantando AB, Kip Jansson Film 1 AB and SwedenBIO. Mr Samuelsson received his MSc in engineering from the Institute of Technology in Linköping. Mr Samuelsson has served as a director in the company since November 2014.